remove_red_eye 530 Views
#Cardiology #Diabetes and Endocrinology #Emergency Medicine #Infectious Diseases #Pathology and Lab Medicine #Pharmacist #Public Health #Pulmonary Medicine
The US Food and Drug Administration (FDA) has expanded the indication for baloxavir marboxil tablets (Xofluza, Genentech) to include people at high risk of developing influenza-related complications.
The new indication regards patients with conditions such as asthma, chronic lung disease, diabetes, heart disease, or morbid obesity and for adults aged 65 years or older.
Baloxavir marboxil has been approved for the treatment of acute uncomplicated influenza in people aged 12 years or older who have been symptomatic for no more than 48 hours. It is given as a single oral dose.